Karsten Henco
Directeur/Membre du Conseil chez ETHRIS GmbH
Profil
Karsten Henco was the founder of QIAGEN Srl (1984), QIAGEN GmbH (1984), and Evotec SE (1993) where he held the title of Chief Executive Officer & Managing Director.
Dr. Henco is also the founder of HS LifeSciences GmbH, QureInvest AG, and QIAGEN NV.
Dr. Henco's current job(s) include being a Director at ETHRIS GmbH, a Member-Executive Board at DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG, and a Member-Supervisory Board at Medovent GmbH.
Dr. Henco's former job(s) include being the Chief Executive Officer & Managing Director at U3 Pharma AG and a Director at CT Atlantic Ltd.Dr. Henco obtained a doctorate degree from Technische Universität Darmstadt.
Postes actifs de Karsten Henco
| Sociétés | Poste | Début |
|---|---|---|
DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG
 DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG Financial ConglomeratesFinance DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG is a private equity firm. The company is based in Munich, Germany. | Corporate Officer/Principal | 17/09/2009 |
Medovent GmbH
 Medovent GmbH Medical SpecialtiesHealth Technology Medovent GmbH engages in the development and manufacture of medical devices made of the biopolymer chitosan. Its main products are a nerve guide used for peripheral nerve injuries and a direct suture for short nerve defects. The company was founded by Rivelino Montenegro and Thomas Freier in 2006 and is headquartered in Mainz, Germany. | Directeur/Membre du Conseil | - |
ETHRIS GmbH
 ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Anciens postes connus de Karsten Henco
| Sociétés | Poste | Fin |
|---|---|---|
QIAGEN GmbH
 QIAGEN GmbH Miscellaneous Commercial ServicesCommercial Services QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany. | Fondateur | - |
| QIAGEN N.V. | Fondateur | - |
Qiagen SRL
 Qiagen SRL Medical SpecialtiesHealth Technology Qiagen SRL is engaged in providing assay technologies. The company is headquartered in Milan, Italy. | Fondateur | - |
| EVOTEC SE | Fondateur | - |
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | President | - |
Formation de Karsten Henco
| Technische Universität Darmstadt | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| QIAGEN N.V. | Health Technology |
| EVOTEC SE | Health Technology |
| Entreprise privées | 9 |
|---|---|
DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG
DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG Financial ConglomeratesFinance DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG is a private equity firm. The company is based in Munich, Germany. | Finance |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
QIAGEN GmbH
QIAGEN GmbH Miscellaneous Commercial ServicesCommercial Services QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany. | Commercial Services |
Medovent GmbH
Medovent GmbH Medical SpecialtiesHealth Technology Medovent GmbH engages in the development and manufacture of medical devices made of the biopolymer chitosan. Its main products are a nerve guide used for peripheral nerve injuries and a direct suture for short nerve defects. The company was founded by Rivelino Montenegro and Thomas Freier in 2006 and is headquartered in Mainz, Germany. | Health Technology |
CT Atlantic Ltd.
 CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Commercial Services |
| HS LifeSciences GmbH | Finance |
QureInvest AG
 QureInvest AG Investment ManagersFinance QureInvest AG targets seed and early stage companies located in Germany and Switzerland. It seeks investments in biotechnology and life sciences firms. | Finance |
Qiagen SRL
Qiagen SRL Medical SpecialtiesHealth Technology Qiagen SRL is engaged in providing assay technologies. The company is headquartered in Milan, Italy. | Health Technology |
ETHRIS GmbH
ETHRIS GmbH Miscellaneous Commercial ServicesCommercial Services ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation. | Commercial Services |
